Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

5.1%

2 terminated out of 39 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

15%

6 trials in Phase 3/4

Results Transparency

40%

8 of 20 completed with results

Key Signals

8 with results91% success

Data Visualizations

Phase Distribution

33Total
Not Applicable (9)
P 1 (6)
P 2 (12)
P 3 (3)
P 4 (3)

Trial Status

Completed20
Recruiting9
Not Yet Recruiting4
Unknown3
Terminated2
Active Not Recruiting1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 20 completed trials

Clinical Trials (39)

Showing 20 of 20 trials
NCT06559150Phase 2RecruitingPrimary

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06603246Phase 1RecruitingPrimary

A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease

NCT07245407RecruitingPrimary

A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE

NCT06487273Not ApplicableRecruitingPrimary

Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

NCT07547436Phase 2Not Yet RecruitingPrimary

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

NCT06663176Phase 1Active Not RecruitingPrimary

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

NCT05743946Phase 4CompletedPrimary

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT07289464Phase 1RecruitingPrimary

A Clinical Study of RSS0343 in Healthy Subjects

NCT05860803Not ApplicableRecruitingPrimary

Breathing Training and Exercise Capacity in Non-CFB

NCT05616221Phase 2CompletedPrimary

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT04594369Phase 3CompletedPrimary

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT07048262Phase 2RecruitingPrimary

Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)

NCT05344508UnknownPrimary

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

NCT06242795Phase 4Recruiting

Hypertonic Saline in NCFB

NCT05495243Phase 2CompletedPrimary

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

NCT05006573Phase 3TerminatedPrimary

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT06981091Phase 2Not Yet RecruitingPrimary

A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

NCT06164470Not ApplicableCompletedPrimary

Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis

NCT06237348Not ApplicableCompletedPrimary

Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH

NCT04322929Phase 2CompletedPrimary

Roflumilast in Non-CF Bronchiectasis Study (2019)

Scroll to load more

Research Network

Activity Timeline